Alfuzosin XR Shortage: What Providers and Prescribers Need to Know in 2026

Patients taking Alfuzosin XR (alfuzosin hydrochloride extended-release 10 mg) for benign prostatic hyperplasia (BPH) may periodically encounter difficulty filling their prescriptions at the retail level. While alfuzosin is not currently listed on the FDA's official drug shortage database, localized supply disruptions are a documented reality for many generic extended-release formulations. This guide provides clinically relevant context for prescribers and other healthcare professionals managing patients on Alfuzosin XR.

Current Supply Status of Alfuzosin XR (2026)

As of early 2026, generic alfuzosin hydrochloride extended-release 10 mg is not declared in shortage by the FDA. Multiple manufacturers — including Rising Pharmaceuticals, Lannett, and other generic producers — hold approved ANDAs and are actively supplying the market. However, the extended-release formulation commands a smaller margin than immediate-release generics, and the supplier base has contracted since Uroxatral's patent expiration. This increases vulnerability to disruptions.

Clinicians should be aware that patient-reported access issues do not always correlate with national-level shortage data. Regional wholesaler allocation imbalances, pharmacy chain-specific purchasing contracts, and formulary changes can all create gaps that affect your patients without triggering formal FDA notification.

Clinical Profile: Key Pharmacology Reminders for Alfuzosin XR

Mechanism: Selective alpha-1A adrenergic receptor antagonist; relaxes smooth muscle in the prostate and bladder neck

Dosing: 10 mg once daily after the same meal — no titration required

Metabolism: Primarily hepatic CYP3A4 — contraindicated with potent CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, cobicistat, and related HIV antiretrovirals)

Ejaculatory effects: Lowest rate among alpha-blockers (~1-3%); preferred for sexually active men compared to tamsulosin (8-18%) or silodosin (>20%)

Contraindications: Moderate/severe hepatic impairment (Child-Pugh B and C); potent CYP3A4 inhibitors; other alpha-1 blockers; hypersensitivity to alfuzosin

Caution with: PDE5 inhibitors (symptomatic hypotension risk); QT-prolonging agents; antihypertensives; grapefruit juice

Therapeutic Alternatives When Alfuzosin XR Is Unavailable

When transitioning a patient off Alfuzosin XR due to supply constraints, consider the following alternatives within the alpha-blocker class. Note that all alpha-blockers share orthostatic hypotension risk and interactions with antihypertensives and PDE5 inhibitors.

Tamsulosin 0.4-0.8 mg once daily (Flomax): First-line for most guidelines; low blood pressure impact; higher ejaculatory dysfunction rate (8-18%); widely available; low cost

Silodosin 8 mg once daily (Rapaflo): Most uroselective; minimal hemodynamic effect; highest rate of retrograde ejaculation (>20%); reduce dose to 4 mg if eGFR 30-50 mL/min; contraindicated with potent CYP3A4 inhibitors

Doxazosin 1-8 mg once daily (Cardura): Non-selective; treats BPH and hypertension; titration required; higher orthostatic hypotension risk; very low cost

Terazosin 1-10 mg once daily (Hytrin): Non-selective; treats BPH and hypertension; titration required; take at bedtime to minimize hypotension; very low cost

For patients where ejaculatory side effects are a primary concern (as may be the case if they were specifically prescribed alfuzosin over tamsulosin), document this in the transition note and counsel the patient about the expected change in ejaculatory function before prescribing an alternative.

Special Populations: Considerations When Switching Alpha-Blockers

Elderly patients: More susceptible to orthostatic hypotension across all alpha-blockers. Counsel patients on slow positional changes, especially when initiating non-selective agents (doxazosin, terazosin) that require titration.

Patients on antihypertensives: All alpha-blockers can cause additive hypotension. Monitor BP at the first 1-2 clinic visits after switching.

Patients on PDE5 inhibitors: Counsel that the hypotension risk applies to all alpha-blockers, not just alfuzosin. Consider timing medications several hours apart.

Patients with planned cataract surgery: Intraoperative Floppy Iris Syndrome (IFIS) has been associated with all alpha-1 blockers. Inform the ophthalmologist of current or prior alpha-blocker use regardless of which agent is prescribed.

How to Help Your Patients Locate Alfuzosin XR

Rather than immediately pivoting to an alternative prescription, consider directing patients to medfinder for providers. medfinder is a paid service that calls pharmacies near the patient to identify which ones have their specific medication in stock. This can resolve many access problems without requiring a new prescription.

For patients who need more background, share our patient-facing article: Alfuzosin XR Shortage Update: What Patients Need to Know in 2026.